Rhumbline Advisers Fulcrum Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $103 Billion
- Q1 2024
A detailed history of Rhumbline Advisers transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 1,657 shares of FULC stock, worth $10,207. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,657
Previous 1,657
-0.0%
Holding current value
$10,207
Previous $11,000
36.36%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding FULC
# of Institutions
135Shares Held
43.7MCall Options Held
3.12MPut Options Held
128K-
Rtw Investments, LP New York, NY5.85MShares$36 Million0.89% of portfolio
-
Cowen And Company, LLC3.71MShares$22.9 Million1.18% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.85MShares$17.5 Million1.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.54MShares$15.6 Million0.0% of portfolio
-
Trv Gp Iv, LLC Boston, MA2.34MShares$14.4 Million10.72% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $321M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...